Earlier insight. Better prepared care.

Early detection, empowered decisions.

ParkinSense is developing a non-invasive digital platform to identify Parkinson's earlier and give clinicians clear, data-backed insight.

Work with us Explore the evidence

Clinician-centred Non-invasive

A person using the ParkinSense assessment on a tablet

Digital assessmentDesigned around people, built for clinical use.

Backed by

Evidence so far

Promising signals, tested in real cohorts.

Early internal results are supporting our next phase of clinical validation. We keep the numbers clear, and the claims grounded.

95%

sensitivity and specificity

in a 962-patient evaluation, including 155 people with Parkinson's.

~1 year

earlier signal

on average among confirmed cases detected before their later clinical diagnosis.

25 min

guided assessment

designed to be completed at home with a helper or in a clinical setting.

£135k

innovation funding

secured to support clinical validation and continued product development.

Early internal results; ongoing validation with clinicians. Figures reflect the latest published ParkinSense website update.

The platform

Specialist insight without specialist equipment.

ParkinSense turns a guided digital assessment into information clinicians can use, while keeping the experience simple for patients.

Enter an assessment code

Non-invasive by design

Software-only assessments make specialist insight easier to reach without adding new hardware or clinical burden.

Signals brought together

A unique model architecture combines assessment data to surface early risk across varied Parkinson's presentations.

Clear for clinicians

Structured summaries, explainable risk scores, and red flags are shaped around real clinical workflows.

Simple for patients

A calm, guided journey can be completed from home or in clinic, with support where it is needed.

Assessment completeReview-ready summary

From assessment to insight

A calm experience on both sides of care.

Patients receive clear guidance through each task. Clinicians receive structured results that are easier to review, compare, and act on.

Guided tasks and accessible instructions
Clinic-scoped, audited staff access
Structured summaries for clinical review

Where it can help

Built for the moments where earlier clarity matters.

Neurology triage

Prioritise referrals with structured summaries and risk scores.

Long-term monitoring

Track change over time and support earlier intervention.

Decision support

Help differentiate Parkinson's from similar neurological conditions.

Research recruitment

Identify suitable participants sooner and accelerate clinical research.

Progress, partnerships and proof.

Follow ParkinSense as we validate the platform, build clinical partnerships and earn recognition in the UK and beyond.

Adam Lockhart, founder and CEO of ParkinSense, selected for Belfast Telegraph 30 Under 30 2026

Recognition 2026

Founder Adam Lockhart named in Belfast's 30 Under 30.

Adam Lockhart, CEO and founder of ParkinSense, has been selected for the Belfast Telegraph 30 Under 30 2026, recognising young people making an impact across Northern Ireland.

Read the story

Awards 2025

Help shape what earlier Parkinson's insight can become.

We're working with clinicians, researchers, healthcare providers, engineers, and partners who want to move early detection forward.

Start a conversation